KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Current Deferred Revenue (2016 - 2025)

Rigel Pharmaceuticals has reported Current Deferred Revenue over the past 15 years, most recently at $1.4 million for Q3 2025.

  • For Q3 2025, Current Deferred Revenue changed 0.0% year-over-year to $1.4 million; the TTM value through Sep 2025 reached $1.4 million, changed 0.0%, while the annual FY2024 figure was $1.4 million, 0.0% changed from the prior year.
  • Current Deferred Revenue for Q3 2025 was $1.4 million at Rigel Pharmaceuticals, roughly flat from $1.4 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $9.5 million in Q1 2021 and troughed at $1.4 million in Q2 2023.
  • A 5-year average of $2.2 million and a median of $1.4 million in 2023 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: surged 362.74% in 2021 and later crashed 77.93% in 2022.
  • Year by year, Current Deferred Revenue stood at $2.6 million in 2021, then plummeted by 47.27% to $1.4 million in 2022, then dropped by 1.02% to $1.4 million in 2023, then changed by 0.0% to $1.4 million in 2024, then changed by 0.0% to $1.4 million in 2025.
  • Business Quant data shows Current Deferred Revenue for RIGL at $1.4 million in Q3 2025, $1.4 million in Q2 2025, and $1.4 million in Q1 2025.